Chemical Compound Review:
Galida (2S)-2-ethoxy-3-[4-[2-(4...
Synonyms:
Tesaglitazar, CHEMBL282686, AZ-242, AG-K-12760, ANW-48037, ...
Ljung,
Bamberg,
Dahllöf,
Kjellstedt,
Oakes,
Ostling,
Svensson,
Camejo,
Ericsson,
Hamrén,
Bergstrand,
Elebring,
Fryklund,
Heijer,
Ohman,
Oakes,
Thalén,
Hultstrand,
Jacinto,
Camejo,
Wallin,
Ljung,
Goldstein,
Rosenstock,
Anzalone,
Tou,
Ohman,
Kamber,
Davis,
Fagerberg,
Edwards,
Halmos,
Lopatynski,
Schuster,
Stender,
Stoa-Birketvedt,
Tonstad,
Halldórsdóttir,
Gause-Nilsson,
- AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. Ljung, B., Bamberg, K., Dahllöf, B., Kjellstedt, A., Oakes, N.D., Ostling, J., Svensson, L., Camejo, G. J. Lipid Res. (2002)
- Tesaglitazar. Kamber, N., Davis, T.M. IDrugs : the investigational drugs journal. (2005)
- Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Zadelaar, A.S., Boesten, L.S., Jukema, J.W., van Vlijmen, B.J., Kooistra, T., Emeis, J.J., Lundholm, E., Camejo, G., Havekes, L.M. Arterioscler. Thromb. Vasc. Biol. (2006)
- Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Fagerberg, B., Edwards, S., Halmos, T., Lopatynski, J., Schuster, H., Stender, S., Stoa-Birketvedt, G., Tonstad, S., Halldórsdóttir, S., Gause-Nilsson, I. Diabetologia (2005)
- Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. Hegarty, B.D., Furler, S.M., Oakes, N.D., Kraegen, E.W., Cooney, G.J. Endocrinology (2004)
- Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist. Samuelsson, S., Johansson, S., Halldórsdóttir, S., Stenhoff, H., Ohman, K.P. Journal of clinical pharmacology. (2006)
- Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Ericsson, H., Hamrén, B., Bergstrand, S., Elebring, M., Fryklund, L., Heijer, M., Ohman, K.P. Drug Metab. Dispos. (2004)
- Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Goldstein, B.J., Rosenstock, J., Anzalone, D., Tou, C., Ohman, K.P. Current medical research and opinion (2006)
- Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Oakes, N.D., Thalén, P., Hultstrand, T., Jacinto, S., Camejo, G., Wallin, B., Ljung, B. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005)
- Tesaglitazar: A promising approach in type 2 diabetes. Cox, S.L. Drugs of today (Barcelona, Spain : 1998) (2006)